Date: | Thursday, September 28, 2023 |
Time: | 9:10 a.m. ET |
Webcast: | A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days. |
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
Source:
2023 GlobeNewswire, Inc., source